NSD2/MMSET/WHSC1

The histone methyltransferase NSD2/MMSET/WHSC1 catalyzes mono- and di-methylation of histone H3 at lysine 36 (H3K36me1/2), regulating chromatin structure and transcriptional fidelity^[1][2]. Mechanistically, NSD2 modifies chromatin accessibility to control gene expression programs associated with cell cycle progression, DNA repair, and metabolic regulation^[3][4][2]. In disease models, NSD2 overexpression promotes tumor aggressiveness in multiple myeloma, prostate cancer, neuroblastoma, and triple-negative breast cancer by activating genes involved in epithelial-mesenchymal transition, autophagy, and glucose metabolism^[5][6][7][8]. NSD2 contributes to oncogenic RAS-driven transcription and enhances DNA damage repair, increasing resistance to chemotherapeutic agents^[9][10]. Compared with related isoforms NSD1 and NSD3, NSD2 exhibits distinct substrate specificity, preferentially catalyzing H3K36 dimethylation and coordinating with EZH2 to reprogram the epigenome^[11][12][2]. The PHD domains of NSD2 are crucial for recruitment to oncogenic gene loci and transcriptional activation, distinguishing its functional engagement from other NSD family members^[13]. For experimental applications, selective NSD2 inhibitors such as KTX-1001 and peptide-based compounds (PTD2) have been developed to suppress H3K36 methylation, demonstrating efficacy in multiple myeloma and breast cancer models^[1][14][15]. These tools enable mechanistic studies of NSD2 function and provide promising avenues for targeted epigenetic therapy.